Acorda boosts sales forecast on Ampyra; Shire looks to sleepiness use for Vyvanse;

@FiercePharma: Architects reveal renderings of new Roche HQ building. News | Follow @FiercePharma 

> Acorda Therapeutics forecast better-than-expected quarterly sales for Ampyra, its new drug to treat walking difficulties in patients with multiple sclerosis. News

> Shire plans to review development pathways with health authorities for Vyvanse as a possible treatment option for excessive daytime sleepiness. Report

> Abbott Laboratories won European approval for its bioabsorbable stent, the first such heart device that disappears after being used to prop open an artery cleared of blockages. Story

> Records show the FDA helped Arizona and California get a quick overseas source of a hard-to-find execution drug even as the agency declared it wouldn't regulate or block the imports. Item

> Four industry trade associations in the U.K., including the pharma body ABPI, have banded together to form a new lobbying group representing life sciences. Report

> Watson Laboratories got the FDA nod for the generic equivalent to Cephalon's Fentora tablets, used to treat breakthrough cancer pain. Article

> Bayer HealthCare sought to reassure healthcare professionals and their patients that a recall of alcohol prep pads distributed with its multiple sclerosis drug did not affect the drug itself. Story

> Merck KGaA announced that it has bought Beijing Skywing Technology, a supplier of cell-culture media products, related technical services and bioreactors for the Chinese biopharmaceutical industry. Report

Biotech News

 @FierceBiotech: Epizyme lands $650M GSK deal

 @JohnCFierce: Planning a fierce happy hour for tweet fans on Wednesday, hosted by fierce publisher @arsalanFierce. Details to come. Follow @JohnCFierce

> CVRs: The next big thing in biotech deals? Report

> Rib-X's antibiotic pipeline garners $20M in funding. Story 

> PPD, Taijitu form new joint venture. Item 

> Lilly, Boehringer team on diabetes venture. News 

Biotech Research News

> Poverty may hold back kids' genetic potential. Story

> Study to follow kids' health from before birth to 21. Item 

> Pharma R&D changing for upcoming patent crisis. News 

> Stem cells from unfertilized eggs may produce new gene therapy. Report 

> New biological systems grown from man-made proteins. Article 

> 'Fishing' expedition might lead to early detection of Alzheimer's. Story

Manufacturing News

> Tweak push vs. pull for supply chain benefit. Story 

> USP revision aids PET drug prep. News 

> Savient to run $10M revalidation at Merck CMO. Item 

> Phony FDA agents assess fines for online drug purchases. Report 

> UK driving school fronts execution drug wholesaler. Story

> Eight critical after phosgene leak at Wanbei Pharma. News 

And Finally... A study of antibodies from people infected with H1N1 swine flu adds proof that scientists are closing in on a "universal" flu shot that could neutralize many types of flu strains. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.